Kolon Life Science Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 25.24 million compared to KRW 27.35 million a year ago. Net income was KRW 464.16 million compared to KRW 778.19 million a year ago. Basic earnings per share from continuing operations was KRW 41 compared to KRW 68 a year ago. Diluted earnings per share from continuing operations was KRW 37 compared to KRW 68 a year ago. Basic earnings per share was KRW 41 compared to KRW 68 a year ago. Diluted earnings per share was KRW 37.
For the nine months, sales was KRW 79.76 million compared to KRW 92.58 million a year ago. Net income was KRW 2,648.09 million compared to KRW 7,007.13 million a year ago. Basic earnings per share from continuing operations was KRW 232 compared to KRW 615 a year ago. Diluted earnings per share from continuing operations was KRW 210 compared to KRW 615 a year ago. Basic earnings per share was KRW 232 compared to KRW 615 a year ago. Diluted earnings per share was KRW 210.